Description
BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research.
Product information
CAS Number: 256498-66-5
Molecular Weight: 420.44
Formula: C21H21FN8O
Chemical Name: 2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-(morpholin-4-yl)pyrimidine-4,6-diamine
Smiles: NC1=NC(=NC(N)=C1N1CCOCC1)C1=NN(CC2=CC=CC=C2F)C2=NC=CC=C21
InChiKey: AQYFUZRYBJBAGZ-UHFFFAOYSA-N
InChi: InChI=1S/C21H21FN8O/c22-15-6-2-1-4-13(15)12-30-21-14(5-3-7-25-21)16(28-30)20-26-18(23)17(19(24)27-20)29-8-10-31-11-9-29/h1-7H,8-12H2,(H4,23,24,26,27)
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vivo:
BAY 41-8543 (10-100 μg/kg; IV) produces small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output. BAY 41-8543 (0.003, 0.01, 0.03, 0.1, and 0.3 mg/kg; iv) produces a dose-dependent and long-lasting decrease in blood pressure in anaesthetized rats. The blood pressure lowering effect of BAY 41-8543 lasts longer than the observation period of 30 min. BAY 41-8543 (0.1, 0.3 and 1.0 mg kg; oral) has maximal blood pressure lowering effects. The blood pressure lowering effects of the highest doses of BAY41-8543 lasts longer than the observation period of 120 min. BAY 41-8543 (3 mg/kg; p.o.; twice daily; for 5 weeks) completely prevents the development of the increase in systolic blood pressure in 18-week-old renin transgenic rats (TGR(mRen2)27) on L-NAME treatment. BAY 41-8543 dramatically increases survival.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.